The Regional Ethical Review Board approves start of Immunicum's planned liver cancer vaccine study

Gothenburg, 2013-08-21 09:12 CEST (GLOBE NEWSWIRE) — On July 22, Immunicum AB (publ) announced that the Medical Products Agency approved the Company’s application for starting a second clinical trial in primary liver cancer. Today, Immunicum announces that the Company also has received authorization from the Regional Ethical Review Board in Gothenburg to start the Company’s upcoming clinical trial.

Immunicum expects to be able to recruit the first patient around the turn of the year. The study will be conducted at Sahlgrenska University Hospital in Gothenburg and will include a total of 12 patients with primary liver cancer who will be treated with the cancer vaccine INTUVAX®. Patients will receive three doses of the vaccine, injected into the primary tumor in the liver, two to three weeks apart, and the Company will study both the tolerability and efficacy of the treatment.

Immunicum’s patented vaccine is based on over 30 years of research in the field of transplantation immunology and activates the body’s own immune system to attack harmful substances like tumor cells. Immunicum’s shares have been traded since April 22, 2013 on NASDAQ OMX First North under the ticker IMMU.

G&W Fondkommission is chosen as the Company’s Certified Adviser.

Tel: +468-503 000 50.

For further information please contact:

Jamal El-Mosleh, CEO of Immunicum, 0703-31 90 51,

About Immunicum AB (publ):

Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®, and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Because the raw material consists of dendritic cells from healthy donors, Immunicum’s products can be produced in large scale. The vaccines have earlier proven efficacy in animal studies and are now undergoing clinical trials in patients.

Keep reading

Faster pace than expected, Immunicum completes treatment of the last patient in its kidney cancer vaccine phase I/II-study already in August